U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537283) titled 'Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy' on April 06.
Brief Summary: This study evaluates the efficacy and safety of coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy.
Study Start Date: Feb. 07, 2023
Study Type: INTERVENTIONAL
Condition:
Epilepsy
Drugs Resistance
Intervention:
DIETARY_SUPPLEMENT: coenzyme Q10
Coenzyme Q10 administered orally as an adjunct to baseline anti-seizure medications for 12 weeks.
DIETARY_SUPPLEMENT: Placebo
Matching placebo capsules administered orally once daily for 12 weeks.
Recruitment Status: COMPLETED
Sponsor: National Cheng-Ku...